![VEGF Receptor 2 antibody [8A01]产品图](https://img1.dxycdn.com/2022/0328/392/4499682063899400453-14.jpg)
- ￥5900
- GeneTex
- 美国
- GTX53464
- 2026年05月27日
- WB, IP, Activation
- Mouse
- Human
企业认证
相关产品推荐更多 >
![C4d antibody [GT1354] (CF488)](https://img1.dxycdn.com/2022/0328/947/1154942844980800453-14.jpg!wh200)
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
细胞污染识别与处理全攻略：5 种常见类型+关键误区Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
hVEGFR2 N-terminal fragment (N30-200)
- 亚型：
IgG1
- 形态：
Liquid
- 保存条件：
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
- 克隆性：
Monoclonal
- 标记物：
Unconjugated
- 适应物种：
Human
- 保质期：
12 months from the shipping date of the product.
- 抗原来源：
Human
- 目录编号：
GTX53464
- 级别：
Primary Antibodies
- 库存：
Available
- 供应商：
GeneTex
- 宿主：
Mouse
- 应用范围：
WB, IP, Activation
- 浓度：
Batch dependent (Please refer to the vial label for the specific concentration.)
- 靶点：
This antibody recognizes hVEGFR-2 in western blot and immunoprecipitation assays. It shows no cross-reactivity with hVEGFR-1.
- 抗体英文名：
VEGF Receptor 2 antibody [8A01]
- 抗体名：
VEGF Receptor 2 抗体 [8A01]
- 规格：
100 μg
Activation assay analysis of HUVECs stimulated with 20ng/ml VEGF or treated with 5.0 and 25 μg/ml GTX53464 VEGF Receptor 2 antibody [8A01] (30mins). Phospho-VEGFR2 was detected with IP-Western for P-Tyrosine.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验PriCells: Primary cells culture with supplement of vascular endothelial growth factor (VEGF)
-1 is less well-defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo).
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
secondary antibody review -- data from 99 publications
cytometry used as a control to detect cell responses targeted antigen 7 Alexa Fluor 488 7 Cy3 8 goat IgG Alexa Fluor 488 1:2000 detect antibody binding in human embryonic kidney 293T cells Invitrogen 9 donkey
技术资料暂无技术资料 索取技术资料
